Literature DB >> 14757155

Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences.

Satomi Onoue1, Asami Matsumoto, Yumiko Nagano, Keiichi Ohshima, Yuki Ohmori, Shizuo Yamada, Ryohei Kimura, Takehiko Yajima, Kazuhisa Kashimoto.   

Abstract

The conformational properties of vasoactive intestinal peptide (VIP) include the N-terminal randomized structure and the C-terminal long alpha-helical structure. We have previously observed that the N-terminal random coil structure plays a crucial role in the receptor-selectivity. Here, to clarify how the formation of the alpha-helix plays a role in its biological functions, we chemically synthesized VIP analogues modified at the C-terminus, mid-chain, and N-terminus of the alpha-helical region, and evaluated the relationship between their alpha-helical contents and their biological activities including relaxant effects on murine stomach and receptor-binding activities. VIP and VIP-(1-27) showed equipotent biological activities with 48% and 50% alpha-helical content, respectively, each of which corresponds to 14 amino acid residues. VIP-(1-26) was 10% and threefold less potent in relaxant and binding activities, respectively, compared with VIP, and its 49% alpha-helical content resulted in 13 residues involved in the alpha-helix. Further truncation from 25 to 21 resulted in decrease in the alpha-helical content from 43% to 29%, corresponding residues from 11 to 6, the relaxant activity from 72% to 4%, and the affinity to the membrane from 60-fold to over 10(4)-fold less potency. In addition, disruption of the mid-chain and the N-terminus in the alpha-helical stretch by oxidation of Met(17) and deletion of Thr(11) also inhibited biological activities. These findings suggest that the presence of alpha-helical structure forming in 14 amino acid residues between position 10 and 23 in VIP is essential to its biological functions and the C-terminal amino acid residues between position 24 and 27 are requisite for this alpha-helical formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757155     DOI: 10.1016/j.ejphar.2003.11.046

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Development of PACAP38 analogue with improved stability: physicochemical and in vitro/in vivo pharmacological characterization.

Authors:  Satomi Onoue; Junko Hanato; Kazuki Kuriyama; Takahiro Mizumoto; Shizuo Yamada
Journal:  J Mol Neurosci       Date:  2010-06-29       Impact factor: 3.444

2.  Possible key residues that determine left gastric artery blood flow response to PACAP in dogs.

Authors:  Mu-Xin Wei; Ping Hu; Ping Wang; Satoru Naruse; Kiyoshi Nokihara; Victor Wray; Tsuyoshi Ozaki
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

Review 3.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

4.  Design, Recombinant Fusion Expression and Biological Evaluation of Vasoactive Intestinal Peptide Analogue as Novel Antimicrobial Agent.

Authors:  Chunlan Xu; Yu Guo; Xiangjin Qiao; Xiaoya Shang; Weining Niu; Mingliang Jin
Journal:  Molecules       Date:  2017-11-14       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.